Holen Sie sich die Stockscreener-App
1.51
7.93%
-0.13
Handel nachbörslich:
1.55
0.04
+2.65%
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
Rare Ebola strain has no treatment; NanoViricides lines up oral NV-387 - Stock Titan
Shelton biotech NanoViricides raises $2M in stock offering - Hartford Business Journal
A. G. P. Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak - TipRanks
NanoViricides Completes $2 Million Registered Direct Offering - TipRanks
NanoViricides Raises $2 Million in Registered Direct Offering With Common and Pre-Funded Warrants - TradingView
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug - citybuzz -
NanoViricides closes $2M direct offering - Yahoo! Finance Canada
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides, Inc - Reuters
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering - ACCESS Newswire
Antiviral developer NanoViricides secures $2M from single institutional investor - Stock Titan
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak - citybuzz -
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak - Yahoo! Finance Canada
New Ebola strain has no treatment — NanoViricides highlights oral NV-387 - Stock Titan
NanoViricides Prices $2 Million Registered Direct Offering - citybuzz -
NanoViricides Advances NV-387 Toward Phase II Trials for MPox in DRC, Expands Orphan Drug Strategy - citybuzz -
NanoViricides to raise $2M in registered direct offering - Yahoo! Finance Canada
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering - ACCESS Newswire
Clinical-stage antiviral firm NanoViricides prices $2M stock-and-warrant deal - Stock Titan
NanoViricides, Inc. Has Filed its Quarterly ReportNV-387 Advancing for Phase II - Lelezard
Broad antiviral NV-387 drug candidate targets measles, mpox, smallpox - Stock Titan
NANOVIRICIDES, INC. 3Q FY2026: Net loss $(1.99M), EPS $(0.09) — 10-Q Summary - TradingView
NanoViricides: Fiscal Q3 Earnings Snapshot - marketscreener.com
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
NNVC Stock Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
TradingKey - TradingKey
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship - citybuzz -
Small cap wrap: Gunnison Copper, Graphene Manufacturing Group, NanoViricides… - Proactive financial news
NanoViricides says hantavirus incident highlights need for antiviral drugs - TipRanks
Does the Recent Hantavirus Outbreak Highlight a Critical Gap for NanoViricides' NV-387 - Kavout
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak - Yahoo Finance
Cruise ship hantavirus deaths spark call for broad-spectrum antiviral drugs - Stock Titan
What NanoViricides (NNVC) bond yields suggest about risk | Q1 2026: Earnings Beat EstimatesCommunity Chart Signals - newser.com
NNVC (NanoViricides) shares surge 9% as EPS beat targets by 23%, defying analyst expectations despite ongoing losses.Spin Off - newser.com
NanoViricides to Present at D. Boral Capital Global Conference as Lead Drug Candidate Advances Toward Phase II Trials - citybuzz -
NanoViricides to Present at D. Boral Capital Global Conference - HarianBasis.co
NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment - Insider Monkey
NanoViricides to Participate at D. Boral Capital Global Conference in NYC - Yahoo Finance
NanoViricides to present at D. Boral Capital Global Conference May 7 in NYC - Pluang
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - Oil & Gas 360
NanoViricides to attend D Boral Capital Conference - Proactive financial news
NanoViricides management offers investor meetings in New York May 7 - Stock Titan
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - Yahoo Finance
NanoViricides’ NV-387 Receives FDA Orphan Drug Designation for Measles Treatment - MEXC
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):